Company intelligence / Profile preview

FS Development Corp. II

San Francisco, California, United Statesmarketscreener.com ↗

Ownership: Private
Development stage: Phase 1

Overview

FS Development Corp. II was a healthcare-focused special purpose acquisition company that completed a business combination with Pardes Biosciences in December 2021, resulting in a publicly traded biopharmaceutical firm developing oral antivirals against SARS-CoV‑2.

Industry: Investors

Drug pipeline

1 asset

PBI-0451

Phase 1

Indications: COVID-19, SARS-CoV-2 infection, Coronavirus infections

Partnerships

PIPE investors included Gilead SciencesRA Capital ManagementFrazier Life Sciences

Beyond the preview

Go deeper on FS Development Corp. II.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FS Development Corp. II.

Explore the full profile